Phase 3 Readout Calendar

Industry-sponsored trials with primary completion in the next 12 months or last 6 months.

Data last updated June 28, 2026 · source: ClinicalTrials.gov

Pro feature

553

Next 6 months

939

Next 12 months

298

Results posted

562

Stale estimates

What you can answer with this page

A confidence-graded calendar of every industry Phase 3 trial reading out in the next 12 months — searchable by sponsor, indication, or NCT, with a per-row staleness flag so you know which dates are still credible.

What's reading out at AstraZeneca in the next 6 months?

Filter by sponsor, then set the window to Next 6 months — it reveals a company's full near-term catalyst slate on one screen.

Which trials are completed but topline isn't out yet?

Filter confidence to “Completed · awaiting.” These are imminent or already-announced reads sitting in the FDAAA 12-month results-posting window.

Are there any GLP-1 or obesity Phase 3 readouts coming up?

Search “obesity” or “GLP-1” in the filter box, and combine with a sponsor such as Lilly or Novo Nordisk for tighter cuts.

Which sponsor-estimated dates haven't been updated in 12+ months?

Filter confidence to “Estimated · stale.” These are the dates most likely to slip — useful for watchlist hygiene and short-thesis scouting.

What's reading out in a specific quarter, like Q2 2026?

Use the window filter (Next 3 / 6 / 12 months) and combine with confidence to shortlist near-term, high-confidence catalysts.

Did a specific trial (NCT ID) read out yet?

Search by NCT ID. The confidence label tells you “Read out” (results posted) vs “Completed · awaiting” vs an estimated date.

Recently read-out results are free; the upcoming calendar shows a free preview, and filters are Pro. How we anchor dates & what we don't claim →

Recently read out & awaiting topline

· 150

Phase 3 trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.

Sponsor	Trial / Asset	Indication	Status	Primary completion	Confidence	NCT
Inventera Inc.	Phase 3 Study of the Efficacy and Safety of MR Arthrography Using the NEMO-103 Injection in Patients With Known or Suspected Shoulder Joint Diseases Asset: NEMO-103 Injection	Rotator Cuff Tear +7	Active Not Recruiting	Q2 2026 2026-04-14	Completed · awaiting Updated 3mo ago	NCT07057037
UCB Biopharma SRL	A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis Asset: Certolizumab pegol	Moderate Chronic Plaque Psoriasis +2	Active Not Recruiting	Q2 2026 2026-04-09	Completed · awaiting Updated 2mo ago	NCT04123795
Alcon Research	Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction Asset: Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution	Ocular Hypertension +1	Completed	Q2 2026 2026-04-06	Completed · awaiting Updated 3mo ago	NCT07082816
Arog Pharmaceuticals, Inc.	Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Asset: Crenolanib	Newly Diagnosed FLT3 Mutated AML	Completed	Q2 2026 2026-04-06	Completed · awaiting Updated 3mo ago	NCT03258931
Ondine Biomedical Inc.	Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections	Surgical Site Infections +3	Completed	Q2 2026 2026-04-03	Completed · awaiting Updated 3mo ago	NCT06702878
Arog Pharmaceuticals, Inc.	Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML Asset: Crenolanib	Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations	Completed	Q2 2026 2026-04-03	Completed · awaiting Updated 3mo ago	NCT03250338
Insmed Incorporated	An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Asset: Treprostinil Palmitil Inhalation Powder	Pulmonary Hypertension +1	Completed	Q2 2026 2026-04-01	Completed · awaiting Updated 2mo ago	NCT05649722
Novartis Pharmaceuticals	Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis Asset: Fingolimod	Multiple Sclerosis (MS)	Active Not Recruiting	Q1 2026 2026-03-25	Completed · awaiting Updated 3mo ago	NCT04926818
Novartis Pharmaceuticals	Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD Asset: TQJ230	Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease	Completed	Q1 2026 2026-03-25	Completed · awaiting Updated 3mo ago	NCT06267560
CSL Behring	The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant Asset: AAT	Acute-graft-versus-host Disease	Completed	Q1 2026 2026-03-19	Completed · awaiting Updated 3mo ago	NCT03805789
Astellas Pharma Inc	A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause Asset: Fezolinetant	Hot Flashes	Completed	Q1 2026 2026-03-19	Completed · awaiting Updated 3mo ago	NCT06206421
Incyte Corporation	A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) Asset: Povorcitinib	NonSegmental Vitiligo	Active Not Recruiting	Q1 2026 2026-03-17	Completed · awaiting Updated 3mo ago	NCT06113471
Eli Lilly and Company	A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk Asset: Orforglipron	Type 2 Diabetes +5	Completed	Q1 2026 2026-03-16	Completed · awaiting Updated 3mo ago	NCT05803421
Sandoz	A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Asset: GME751	Metastatic NSCLC	Completed	Q1 2026 2026-03-16	Completed · awaiting Updated 3mo ago	NCT06159790
Regeneron Pharmaceuticals	Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma Asset: Fianlimab	Melanoma	Active Not Recruiting	Q1 2026 2026-03-12	Completed · awaiting Updated 3mo ago	NCT05352672
Merck Sharp & Dohme LLC	A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) Asset: Pembrolizumab (+) Berahyaluronidase alfa	Lung Cancer +1	Active Not Recruiting	Q1 2026 2026-03-12	Completed · awaiting Updated 3mo ago	NCT06698042
argenx	A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). Asset: efgartigimod	Primary Immune Thrombocytopenia	Completed	Q1 2026 2026-03-11	Completed · awaiting Updated 4mo ago	NCT04225156
Amgen	Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer Asset: Romiplostim	Chemotherapy-induced Thrombocytopenia	Active Not Recruiting	Q1 2026 2026-03-10	Completed · awaiting Updated 3mo ago	NCT03937154
AstraZeneca	Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations Asset: Placebo	Chronic Obstructive Pulmonary Disease (COPD)	Active Not Recruiting	Q1 2026 2026-03-06	Completed · awaiting Updated 4mo ago	NCT06040086
Novo Nordisk A/S	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Asset: Cagrilintide	Type 2 Diabetes	Completed	Q1 2026 2026-03-04	Completed · awaiting Updated 3mo ago	NCT06221969
Eli Lilly and Company	A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Asset: Mirikizumab	Ulcerative Colitis	Active Not Recruiting	Q1 2026 2026-03-04	Completed · awaiting Updated 3mo ago	NCT03519945
Sanofi	Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa Asset: avalglucosidase alfa	Glycogen Storage Disease Type II	Active Not Recruiting	Q1 2026 2026-03-02	Completed · awaiting Updated 3mo ago	NCT04910776
Sarfez Pharmaceuticals, Inc.	Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone Asset: Torsemide and Spironolactone tablet	Bioavailability Heathy Volunteers	Completed	Q1 2026 2026-02-28	Completed · awaiting Updated 4mo ago	NCT07046975
AstraZeneca	Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).	Chronic Obstructive Pulmonary Disease (COPD)	Completed	Q1 2026 2026-02-26	Completed · awaiting Updated 4mo ago	NCT05742802
Incyte Corporation	A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) Asset: Povorcitinib	NonSegmental Vitiligo	Active Not Recruiting	Q1 2026 2026-02-24	Completed · awaiting Updated 4mo ago	NCT06113445
Novartis Pharmaceuticals	Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission Asset: Secukinumab 300 mg, s.c.	Giant Cell Arteritis	Completed	Q1 2026 2026-02-24	Completed · awaiting Updated 4mo ago	NCT05380453
AstraZeneca	Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC Asset: Tremelimumab	Hepatocellular Carcinoma	Active Not Recruiting	Q1 2026 2026-02-23	Completed · awaiting Updated 3mo ago	NCT05301842
Karyopharm Therapeutics Inc	Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Asset: Selinexor	Myelofibrosis	Active Not Recruiting	Q1 2026 2026-02-20	Completed · awaiting Updated 3mo ago	NCT04562389
Novartis Pharmaceuticals	A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia Asset: Ianalumab	Warm Autoimmune Hemolytic Anemia (wAIHA)	Active Not Recruiting	Q1 2026 2026-02-20	Completed · awaiting Updated 4mo ago	NCT05648968
Pfizer	Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC Asset: talazoparib plus enzalutamide	Prostate Cancer	Active Not Recruiting	Q1 2026 2026-02-18	Completed · awaiting Updated 3mo ago	NCT04821622
Celltrion	A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis Asset: CT-P55	Plaque Psoriasis	Active Not Recruiting	Q1 2026 2026-02-18	Completed · awaiting Updated 4mo ago	NCT06630559
Bristol-Myers Squibb	A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer Asset: Nivolumab	Urinary Bladder Neoplasms +1	Active Not Recruiting	Q1 2026 2026-02-16	Completed · awaiting Updated 3mo ago	NCT03661320
RDC Clinical Pty Ltd	Effect of Maolactin™ FMR on Exercise Recovery, Inflammation and Muscle Comfort in an Otherwise Healthy Population Asset: Maolactin	Chronic Inflammation +3	Completed	Q1 2026 2026-02-16	Completed · awaiting Updated 4mo ago	NCT06444763
Astellas Pharma Global Development…	A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity Asset: mirabegron	Neurogenic Detrusor Overactivity	Active Not Recruiting	Q1 2026 2026-02-16	Completed · awaiting Updated 4mo ago	NCT05621616
Beijing Suncadia Pharmaceuticals C…	A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty Asset: SHR-2004 injection	Prevention of Arterial and Venous Thrombosis	Completed	Q1 2026 2026-02-15	Completed · awaiting Updated 3mo ago	NCT06825416
Boston Scientific Corporation	MANDARIN (S6371)	Inoperable Hepatocellular Carcinoma	Active Not Recruiting	Q1 2026 2026-02-13	Completed · awaiting Updated 3mo ago	NCT05016245
Viridian Therapeutics, Inc.	An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) Asset: VRDN-003	Thyroid Eye Disease	Active Not Recruiting	Q1 2026 2026-02-12	Completed · awaiting Updated 3mo ago	NCT06625411
Taisho Pharmaceutical Indonesia	Counterpain PXM Versus Diclofenac Versus Piroxicam Asset: Piroxicam plus Counterirritant (brand name Counterpain® PXM).	Ankle Sprain +4	Completed	Q1 2026 2026-02-12	Completed · awaiting Updated 4mo ago	NCT07475663
PTC Therapeutics	Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD) Asset: Ataluren	Duchenne Muscular Dystrophy	Completed	Q1 2026 2026-02-10	Completed · awaiting Updated 4mo ago	NCT01247207
UCB Biopharma SRL	A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis Asset: Bimekizumab	Psoriatic Arthritis	Active Not Recruiting	Q1 2026 2026-02-06	Completed · awaiting Updated 3mo ago	NCT06624228
Janssen Research & Development, LLC	A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome Asset: Milvexian	Acute Coronary Syndrome	Completed	Q1 2026 2026-02-06	Completed · awaiting Updated 3mo ago	NCT05754957
Forma Therapeutics, Inc.	A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS) Asset: Etavopivat Tablets Low dose	Sickle Cell Disease	Active Not Recruiting	Q1 2026 2026-02-06	Completed · awaiting Updated 3mo ago	NCT04624659
Daewoong Pharmaceutical Co. LTD.	A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension Asset: DWC202405	Essential Hypertension	Completed	Q1 2026 2026-02-05	Completed · awaiting Updated 4mo ago	NCT06671392
Pfizer	A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo Asset: Ritlecitinib	Stable Nonsegmental Vitiligo +1	Completed	Q1 2026 2026-02-05	Completed · awaiting Updated 4mo ago	NCT05583526
AbbVie	A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin Quality	Skin Quality Deficit	Completed	Q1 2026 2026-02-05	Completed · awaiting Updated 5mo ago	NCT06547125
AbbVie	Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma	Open-Angle Glaucoma	Completed	Q1 2026 2026-02-04	Completed · awaiting Updated 4mo ago	NCT05411198
CSPC Baike (Shandong) Biopharmaceu…	A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus Asset: TG103	Type 2 Diabetes Mellitus	Completed	Q1 2026 2026-02-03	Completed · awaiting Updated 3mo ago	NCT06235086
Immunovant Sciences GmbH	Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease Asset: Batoclimab	Thyroid Eye Disease	Completed	Q1 2026 2026-02-03	Completed · awaiting Updated 3mo ago	NCT05524571
Merck Sharp & Dohme LLC	A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) Asset: Belzutifan	Carcinoma, Renal Cell	Active Not Recruiting	Q1 2026 2026-02-02	Completed · awaiting Updated 4mo ago	NCT04586231
United Therapeutics	Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Asset: Placebo	Idiopathic Pulmonary Fibrosis +1	Completed	Q1 2026 2026-02-02	Completed · awaiting Updated 3mo ago	NCT04708782
Tasly Pharmaceutical Group Co., Ltd	A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis Asset: pimavanserin tartrate	Parkinson's Disease Psychosis	Completed	Q1 2026 2026-02-01	Completed · awaiting Updated 4mo ago	NCT06068465
Hoffmann-La Roche	A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) Asset: Giredestrant	Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer	Active Not Recruiting	Q1 2026 2026-01-30	Completed · awaiting Updated 5mo ago	NCT04546009
Mundipharma Research Limited	Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Asset: Rezafungin for Injection	Candidemia +9	Completed	Q1 2026 2026-01-29	Completed · awaiting Updated 3mo ago	NCT04368559
Vertex Pharmaceuticals Incorporated	Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older Asset: ELX/TEZ/IVA	Cystic Fibrosis	Completed	Q1 2026 2026-01-29	Completed · awaiting Updated 4mo ago	NCT05153317
Novartis Pharmaceuticals	Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab Asset: Ofatumumab approved dose	Relapsing Multiple Sclerosis (RMS)	Active Not Recruiting	Q1 2026 2026-01-28	Completed · awaiting Updated 3mo ago	NCT06869785
Colgate Palmolive	The Efficacy of a Battery Toothbrush in the Reduction of Established Plaque and Gingivitis Asset: Total Active Prevention Fresh Toothpaste + Colgate Total Active Prevention Battery Toothbrush	Plaque +1	Completed	Q1 2026 2026-01-28	Completed · awaiting Updated 5mo ago	NCT07224828
Hoffmann-La Roche	A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) Asset: Fenebrutinib	Relapsing Multiple Sclerosis	Active Not Recruiting	Q1 2026 2026-01-27	Completed · awaiting Updated 5mo ago	NCT04586010
Cassiopea SpA	A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss Asset: Clascoterone 5% solution	Alopecia, Androgenetic	Completed	Q1 2026 2026-01-26	Completed · awaiting Updated 4mo ago	NCT05910450
CSPC Baike (Shandong) Biopharmaceu…	A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus Asset: TG103	Type 2 Diabetes Mellitus	Completed	Q1 2026 2026-01-23	Completed · awaiting Updated 3mo ago	NCT06258148
Eli Lilly and Company	Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) Asset: Retatrutide	Diabetes Type 2	Completed	Q1 2026 2026-01-22	Completed · awaiting Updated 4mo ago	NCT06354660
AstraZeneca	A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). Asset: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate	Chronic Obstructive Pulmonary Disease	Completed	Q1 2026 2026-01-22	Completed · awaiting Updated 4mo ago	NCT06067828
Sun Pharmaceutical Industries Limi…	A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. Asset: Tildrakizumab 100 mg	Moderate to Severe Genital Psoriasis	Active Not Recruiting	Q1 2026 2026-01-21	Completed · awaiting Updated 3mo ago	NCT06611163
Eli Lilly and Company	A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities Asset: Tirzepatide	Overweight +1	Completed	Q1 2026 2026-01-20	Completed · awaiting Updated 3mo ago	NCT06047548
Takeda	A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases Asset: TAK-881	Primary Immunodeficiency Diseases (PID)	Completed	Q1 2026 2026-01-20	Completed · awaiting Updated 5mo ago	NCT05755035
Sanofi	Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults Asset: Yellow fever vaccine (live)	Yellow Fever Immunization	Completed	Q1 2026 2026-01-20	Completed · awaiting Updated 5mo ago	NCT07002060
IBSA Institut Biochimique SA	Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer. Asset: Progesterone-IBSA Injectable Solution	Infertility	Active Not Recruiting	Q1 2026 2026-01-20	Completed · awaiting Updated 5mo ago	NCT04549116
AstraZeneca	Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations Asset: Tozorakimab	Chronic Obstructive Pulmonary Disease (COPD)	Completed	Q1 2026 2026-01-19	Completed · awaiting Updated 3mo ago	NCT05166889
AstraZeneca	Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. Asset: Tozorakimab	Chronic Obstructive Pulmonary Disease (COPD)	Completed	Q1 2026 2026-01-19	Completed · awaiting Updated 3mo ago	NCT05158387
Nanjing Zenshine Pharmaceuticals	Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza Asset: ZX-7101A for oral suspension	Respiratory Viral Infection	Completed	Q1 2026 2026-01-16	Completed · awaiting Updated 3mo ago	NCT07095257
Lipocine Inc.	A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD Asset: LPCN 1154A	Depression, Postpartum +5	Completed	Q1 2026 2026-01-16	Completed · awaiting Updated 4mo ago	NCT06979544
Bristol-Myers Squibb	A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM Asset: mavacamten	Hypertrophic Cardiomyopathy +2	Completed	Q1 2026 2026-01-16	Completed · awaiting Updated 5mo ago	NCT03723655
Dizal Pharmaceuticals	A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) Asset: sunvozertinib	Non-small Cell Lung Cancer	Active Not Recruiting	Q1 2026 2026-01-16	Completed · awaiting Updated 5mo ago	NCT05668988
Yuhan Corporation	Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis Asset: YHP2401	Acute Bronchitis	Completed	Q1 2026 2026-01-15	Completed · awaiting Updated 5mo ago	NCT07111468
Immedica Pharma AB	Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia Asset: Chronocort	Congenital Adrenal Hyperplasia	Completed	Q1 2026 2026-01-15	Completed · awaiting Updated 5mo ago	NCT05299554
KalVista Pharmaceuticals, Ltd.	Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II Asset: KVD900 150 mg	Hereditary Angioedema	Completed	Q1 2026 2026-01-15	Completed · awaiting Updated 5mo ago	NCT06467084
Shanghai Hutchison Pharmaceuticals…	Efficacy and Safety of Shenqi Sherong Pill in Participants With Cervical Spondylotic Myelopathy Asset: Shenqi Sherong Pill	Cervical Spondylotic Myelopathy	Completed	Q1 2026 2026-01-14	Completed · awaiting Updated 2mo ago	NCT06377072
Palvella Therapeutics, Inc.	SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations Asset: QTORIN 3.9% Rapamycin Anhydrous Gel	Microcystic Lymphatic Malformation	Active Not Recruiting	Q1 2026 2026-01-14	Completed · awaiting Updated 3mo ago	NCT06239480
Merck Sharp & Dohme LLC	Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) Asset: pembrolizumab	Hodgkin Lymphoma	Completed	Q1 2026 2026-01-14	Completed · awaiting Updated 5mo ago	NCT02684292
Amgen	A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease Asset: Teprotumumab	Thyroid Eye Disease	Active Not Recruiting	Q1 2026 2026-01-14	Completed · awaiting Updated 5mo ago	NCT06248619
Eli Lilly and Company	A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Asset: Lebrikizumab	Atopic Dermatitis +1	Active Not Recruiting	Q1 2026 2026-01-14	Completed · awaiting Updated 6mo ago	NCT05559359
Seagen, a wholly owned subsidiary …	Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Asset: Brentuximab vedotin	Diffuse Large B-cell Lymphoma	Active Not Recruiting	Q1 2026 2026-01-12	Completed · awaiting Updated 3mo ago	NCT04404283
Janssen Research & Development, LLC	A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis Asset: Ustekinumab	Arthritis, Juvenile	Active Not Recruiting	Q1 2026 2026-01-12	Completed · awaiting Updated 3mo ago	NCT05083182
Pfizer	A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma Asset: Encorafenib	Melanoma	Active Not Recruiting	Q1 2026 2026-01-12	Completed · awaiting Updated 3mo ago	NCT04657991
Xenon Pharmaceuticals Inc.	A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures Asset: XEN1101	Focal Onset Seizures	Completed	Q1 2026 2026-01-12	Completed · awaiting Updated 4mo ago	NCT05614063
Eli Lilly and Company	A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) Asset: Selpercatinib	Carcinoma, Non-Small-Cell Lung	Active Not Recruiting	Q1 2026 2026-01-12	Completed · awaiting Updated 4mo ago	NCT04819100
Chiesi Farmaceutici S.p.A.	A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD Asset: Beclomethasone Dipropionate	COPD +1	Completed	Q1 2026 2026-01-12	Completed · awaiting Updated 5mo ago	NCT04320342
RDC Clinical Pty Ltd	LC-Plasma for Preventing URTIs and Reducing Symptoms	Healthy Volunteer +1	Completed	Q1 2026 2026-01-10	Completed · awaiting Updated 4mo ago	NCT06827327
Eli Lilly and Company	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight Asset: Ixekizumab	Psoriasis +1	Completed	Q1 2026 2026-01-08	Completed · awaiting Updated 6mo ago	NCT06588283
Alexion Pharmaceuticals, Inc.	Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP Asset: ALXN1850	Hypophosphatasia	Active Not Recruiting	Q1 2026 2026-01-06	Completed · awaiting Updated 5mo ago	NCT06079359
Chengdu Suncadia Medicine Co., Ltd.	Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment Asset: HRS-5965 capsule	Paroxysmal Nocturnal Hemoglobinuria	Completed	Q1 2026 2026-01-06	Completed · awaiting Updated 6mo ago	NCT06715943
Alexion Pharmaceuticals, Inc.	Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) Asset: Ravulizumab	Immunoglobulin A Nephropathy +1	Active Not Recruiting	Q1 2026 2026-01-05	Completed · awaiting Updated 3mo ago	NCT06291376
United Therapeutics	A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients Asset: Ralinepag	PAH +10	Completed	Q4 2025 2025-12-31	Completed · awaiting Updated 3mo ago	NCT03626688
Innovent Biologics (Suzhou) Co. Ltd.	A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC Asset: IBI310	Hepatocellular Carcinoma	Completed	Q4 2025 2025-12-31	Completed · awaiting Updated 4mo ago	NCT04720716
RDC Clinical Pty Ltd	Effectiveness of a Grape Seed Extract on Circulatory Measures in Healthy Adults Asset: Grape Seed Extract	Circulatory; Change	Completed	Q4 2025 2025-12-31	Completed · awaiting Updated 4mo ago	NCT06440252
Bayer	A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease Asset: Finerenone (BAY94-8862)	Non-diabetic Chronic Kidney Disease	Completed	Q4 2025 2025-12-31	Completed · awaiting Updated 5mo ago	NCT05047263
Hoffmann-La Roche	A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer Asset: Atezolizumab	Non-Small Cell Lung Cancer	Active Not Recruiting	Q4 2025 2025-12-30	Completed · awaiting Updated 3mo ago	NCT05047250
Colgate Palmolive	Clinical Investigation of PerioGard (Test) Regimen Asset: PeriGuard regimen	Gingivitis	Completed	Q4 2025 2025-12-30	Completed · awaiting Updated 4mo ago	NCT07210138
Quoin Pharmaceuticals	Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome Asset: QRX003-2% Lotion	Netherton Syndrome	Active Not Recruiting	Q4 2025 2025-12-30	Completed · awaiting Updated 4mo ago	NCT05521438
Sarfez Pharmaceuticals, Inc.	A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects	Bioavailability Heathy Volunteers	Completed	Q4 2025 2025-12-30	Completed · awaiting Updated 4mo ago	NCT07043634
Sarfez Pharmaceuticals, Inc.	Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects Asset: 10 mg Torsemide tablet	Bioequivalence Study in Healthy Subjects +1	Completed	Q4 2025 2025-12-30	Completed · awaiting Updated 4mo ago	NCT07015671
Mineralys Therapeutics Inc.	Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension Asset: lorundrostat	Hypertension	Active Not Recruiting	Q4 2025 2025-12-30	Completed · awaiting Updated 5mo ago	NCT05968430
Hoffmann-La Roche	A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer Asset: Atezolizumab	Non-Small Cell Lung Cancer	Completed	Q4 2025 2025-12-30	Completed · awaiting Updated 5mo ago	NCT04294810
Bayer	A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema Asset: 8 mg aflibercept (BAY 86-5321) (High Dose)	Diabetic Macular Edema	Completed	Q4 2025 2025-12-29	Completed · awaiting Updated 3mo ago	NCT06422507
Alexion Pharmaceuticals, Inc.	Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG Asset: Eculizumab	Generalized Myasthenia Gravis (gMG) +1	Completed	Q4 2025 2025-12-29	Completed · awaiting Updated 6mo ago	NCT06764160
Sanofi Pasteur, a Sanofi Company	Phase 3 Single Arm, Open Study on vYF in Adults Asset: Yellow fever vaccine (live)	Yellow Fever	Completed	Q4 2025 2025-12-25	Completed · awaiting Updated 5mo ago	NCT07222059
Haisco Pharmaceutical Group Co., L…	Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia Asset: HSK39297 tablets	Paroxysmal Nocturnal Haemoglobinuria (PNH)	Completed	Q4 2025 2025-12-23	Completed · awaiting Updated 5mo ago	NCT07052838
SynOx Therapeutics Limited	Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) Asset: Emactuzumab	TGCT	Active Not Recruiting	Q4 2025 2025-12-23	Completed · awaiting Updated 5mo ago	NCT05417789
Amzell	A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms Asset: AMZ001 Diclofenac gel	Osteoarthritis of Knee +1	Completed	Q4 2025 2025-12-22	Completed · awaiting Updated 6mo ago	NCT06693648
Hoffmann-La Roche	A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy Asset: Obinutuzumab	Primary Membranous Nephropathy	Active Not Recruiting	Q4 2025 2025-12-22	Completed · awaiting Updated 3mo ago	NCT04629248
Rhythm Pharmaceuticals, Inc.	EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway Asset: Setmelanotide	Obesity +1	Active Not Recruiting	Q4 2025 2025-12-22	Completed · awaiting Updated 5mo ago	NCT05093634
Merck Sharp & Dohme LLC	V114 and Acute Otitis Media (V114-032/PNEU-ERA) Asset: V114	Acute Otitis Media (AOM)	Completed	Q4 2025 2025-12-22	Completed · awaiting Updated 5mo ago	NCT04193215
Pfizer	Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis Asset: Abrocitinib 100 mg	Dermatitis, Atopic	Completed	Q4 2025 2025-12-22	Completed · awaiting Updated 6mo ago	NCT03422822
Colgate Palmolive	Clinical Study to Evaluate the Tooth Whitening Efficacy of a New NextGen In-office Whitening System Asset: Beaming White	Health Adult Subjects	Completed	Q4 2025 2025-12-21	Completed · awaiting Updated 6mo ago	NCT07225478
Boston Scientific Corporation	A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort	In-Stent Restenosis	Active Not Recruiting	Q4 2025 2025-12-19	Completed · awaiting Updated 4mo ago	NCT06492174
QED Therapeutics, a BridgeBio comp…	A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia Asset: Infigratinib 0.25 mg/kg/day	Achondroplasia	Completed	Q4 2025 2025-12-18	Completed · awaiting Updated 4mo ago	NCT06164951
Quince Therapeutics S.p.A.	Evaluate the Neurological Effects of EryDex on Subjects With A-T Asset: Dexamethasone sodium phosphate	Ataxia Telangiectasia	Completed	Q4 2025 2025-12-17	Completed · awaiting Updated 6mo ago	NCT06193200
Sanofi	A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease Asset: Venglustat (GZ402671)	Fabry Disease	Active Not Recruiting	Q4 2025 2025-12-17	Completed · awaiting Updated 5mo ago	NCT05206773
Boehringer Ingelheim	A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight	Obesity +1	Completed	Q4 2025 2025-12-12	Completed · awaiting Updated 2mo ago	NCT06066528
Sanofi	Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3 Asset: Eliglustat GZ385660	Gaucher's Disease Type I +1	Completed	Q4 2025 2025-12-12	Completed · awaiting Updated 6mo ago	NCT03485677
Boehringer Ingelheim	Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma Asset: Brigimadlin	Liposarcoma, Dedifferentiated	Completed	Q4 2025 2025-12-12	Completed · awaiting Updated 6mo ago	NCT06058793
Apellis Pharmaceuticals, Inc.	Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe Asset: APL-2, Pegcetacoplan	Geographic Atrophy Secondary to Age-related Macular Degeneration	Completed	Q4 2025 2025-12-12	Completed · awaiting Updated 7mo ago	NCT07214740
Colgate Palmolive	Clinical Study to Evaluate the Anti-cavity Efficacy of Three Dentifrices: An In Situ Model Asset: Fluoride free toothpaste in a chalk base	Demineralization +3	Completed	Q4 2025 2025-12-11	Completed · awaiting Updated 5mo ago	NCT07134231
Eli Lilly and Company	A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine Asset: Galcanezumab	Chronic Migraine	Active Not Recruiting	Q4 2025 2025-12-10	Completed · awaiting Updated 4mo ago	NCT04616326
Rose Research Center, LLC	Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders Asset: Nicoderm	Smoking Cessation +1	Completed	Q4 2025 2025-12-09	Completed · awaiting Updated 5mo ago	NCT06554873
GlaxoSmithKline	A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old) Asset: rMenB+OMV NZ vaccine	Meningitis	Completed	Q4 2025 2025-12-08	Completed · awaiting Updated 3mo ago	NCT06995430
Novo Nordisk A/S	A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight Asset: Cagrilintide	Obesity	Completed	Q4 2025 2025-12-08	Completed · awaiting Updated 5mo ago	NCT06131437
AbbVie	A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants	Facial Volume Deficit	Completed	Q4 2025 2025-12-05	Completed · awaiting Updated 6mo ago	NCT05818709
Boehringer Ingelheim	A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease Asset: Survodutide	Obesity	Completed	Q4 2025 2025-12-03	Completed · awaiting Updated 7mo ago	NCT06176365
Immunome, Inc.	A Study of AL102 in Patients With Progressing Desmoid Tumors Asset: AL102	Desmoid +1	Active Not Recruiting	Q4 2025 2025-12-03	Completed · awaiting Updated 5mo ago	NCT04871282
Boehringer Ingelheim	A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight	Obesity	Completed	Q4 2025 2025-12-02	Completed · awaiting Updated 4mo ago	NCT06066515
BeiGene	Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer Asset: Pamiparib capsule	Ovarian Cancer	Active Not Recruiting	Q4 2025 2025-12-01	Completed · awaiting Updated 4mo ago	NCT03519230
AbbVie	Open-label Trial in Parkinson's Disease (PD) Asset: Tavapadon	Parkinson Disease	Completed	Q4 2025 2025-12-01	Completed · awaiting Updated 6mo ago	NCT04760769
Apellis Pharmaceuticals, Inc.	Pegcetacoplan Long Term Safety and Efficacy Extension Study Asset: Pegcetacoplan	PNH	Completed	Q4 2025 2025-11-29	Completed · awaiting Updated 3mo ago	NCT03531255
Angitia Biopharmaceuticals	A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion Asset: AGA111	Degenerative Disc Disease	Active Not Recruiting	Q4 2025 2025-11-28	Completed · awaiting Updated 5mo ago	NCT06115512
GB002, Inc.	Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) Asset: Placebo	Pulmonary Arterial Hypertension	Completed	Q4 2025 2025-11-27	Completed · awaiting Updated 3mo ago	NCT05934526
Vincentage Pharma Co., Ltd	A Research Study of VCT220 in Adult Chinese Participants With Obesity Asset: VCT220	Obesity +1	Active Not Recruiting	Q4 2025 2025-11-25	Completed · awaiting Updated 3mo ago	NCT06939296
Sanofi	A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2) Asset: Amlitelimab	Dermatitis Atopic	Completed	Q4 2025 2025-11-25	Completed · awaiting Updated 4mo ago	NCT06181435
Hutchmed	HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Asset: HMPL-523(300mg PO QD)	Warm Antibody Autoimmune Hemolytic Anemia	Active Not Recruiting	Q4 2025 2025-11-25	Completed · awaiting Updated 4mo ago	NCT05535933
Bristol-Myers Squibb	A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy Asset: Mavacamten	Cardiomyopathy, Hypertrophic	Active Not Recruiting	Q4 2025 2025-11-25	Completed · awaiting Updated 7mo ago	NCT06253221
AbbVie	A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence Asset: BOTOX	Masseter Muscle Prominence	Completed	Q4 2025 2025-11-25	Completed · awaiting Updated 7mo ago	NCT06387394
AstraZeneca	A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension Asset: Baxdrostat	Uncontrolled Hypertension +1	Completed	Q4 2025 2025-11-24	Completed · awaiting Updated 3mo ago	NCT06344104
AstraZeneca	Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China Asset: Nirsevimab	Lower Respiratory Tract Infection	Completed	Q4 2025 2025-11-24	Completed · awaiting Updated 3mo ago	NCT05110261
Colgate Palmolive	Efficacy of a Toothpaste Containing Hydrogen Peroxide as Compared to a Regular Fluoride Toothpaste Without Hydrogen Peroxide in the Immediate Removal of Tooth Stains After a Single Brushing. Asset: Optic White Adv Sparkling White (2%HP) Toothpaste	Whitening	Completed	Q4 2025 2025-11-24	Completed · awaiting Updated 7mo ago	NCT07276672
Insmed Incorporated	Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex Asset: ALIS	Mycobacterium Infections, Nontuberculous	Completed	Q4 2025 2025-11-21	Completed · awaiting Updated 5mo ago	NCT04677569
CSL Behring	Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks Asset: CSL312	Hereditary Angioedema	Completed	Q4 2025 2025-11-21	Completed · awaiting Updated 5mo ago	NCT04739059
Eli Lilly and Company	A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) Asset: Orforglipron	Obesity +1	Completed	Q4 2025 2025-11-21	Completed · awaiting Updated 7mo ago	NCT06584916
Hoffmann-La Roche	A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Asset: Satralizumab	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)	Active Not Recruiting	Q4 2025 2025-11-20	Completed · awaiting Updated 3mo ago	NCT05271409
Cutia Therapeutics（Wuxi）Co.,Ltd	A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101) Asset: CU-20101 treatment for Moderate to Severe Glabellar Striae	Glabellar Frown Lines	Completed	Q4 2025 2025-11-20	Completed · awaiting Updated 5mo ago	NCT06585696
Amgen	A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis Asset: Apremilast	Plaque Psoriasis	Active Not Recruiting	Q4 2025 2025-11-20	Completed · awaiting Updated 7mo ago	NCT05565560
AbbVie	A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants Asset: BOTOX	Masseter Muscle Prominence	Completed	Q4 2025 2025-11-20	Completed · awaiting Updated 7mo ago	NCT06068855

Upcoming readouts — next 12 months

· 300

Industry Phase 3 trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.

Sponsor	Trial / Asset	Indication	Status	Primary completion	Confidence	NCT
Novartis Pharmaceuticals	Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy Asset: Iptacopan	Atypical Hemolytic Uremic Syndrome	Completed	Q3 2026 2026-07-09 (est.)	Estimated · fresh Updated 3mo ago	NCT04889430
Bristol-Myers Squibb	A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Asset: Nivolumab	Hepatocellular Carcinoma	Active Not Recruiting	Q3 2026 2026-07-09 (est.)	Estimated · fresh Updated 3mo ago	NCT04039607
Pharming Technologies B.V.	Pediatric Patients Aged 1 to 6 Years With APDS Asset: Leniolisib	APDS	Active Not Recruiting	Q3 2026 2026-07-09 (est.)	Estimated · aging Updated 8mo ago	NCT05693129
Pfizer	A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). Asset: PF-06821497	Metastatic Castrate Resistant Prostate Cancer (mCRPC)	Active Not Recruiting	Q3 2026 2026-07-13 (est.)	Estimated · fresh Updated 3mo ago	NCT06551324
Incyte Corporation	A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis Asset: Ruxolitinib	Atopic Dermatitis	Active Not Recruiting	Q3 2026 2026-07-13 (est.)	Estimated · aging Updated 7mo ago	NCT06832618
AstraZeneca	Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis Asset: Tezepelumab	Eosinophilic Esophagitis	Active Not Recruiting	Q3 2026 2026-07-14 (est.)	Estimated · fresh Updated 3mo ago	NCT05583227
Regeneron Pharmaceuticals	A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) Asset: mibavademab	Generalized Lipodystrophy	Active Not Recruiting	Q3 2026 2026-07-14 (est.)	Estimated · fresh Updated 3mo ago	NCT06548100
Alexion Pharmaceuticals, Inc.	Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis Asset: Ravulizumab	Generalized Myasthenia Gravis +1	Active Not Recruiting	Q3 2026 2026-07-15 (est.)	Estimated · fresh Updated 3mo ago	NCT05644561
Sinovac (Dalian) Vaccine Technolog…	Second Dose of Varicella Vaccine in Healthy Children Asset: PROVARIX	Varicella (Chickenpox) +1	Recruiting	Q3 2026 2026-07-15 (est.)	Estimated · fresh Updated 4mo ago	NCT07475000
Price Vision Group	Corneal Crosslinking for Treatment of Corneal Neovascularization	Corneal Neovascularization	Recruiting	Q3 2026 2026-07-15 (est.)	Estimated · aging Updated 11mo ago	NCT04787471
GlaxoSmithKline	A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease Asset: RSVPreF3 OA vaccine	Respiratory Syncytial Virus Infections	Recruiting	Q3 2026 2026-07-16 (est.)	Estimated · fresh Updated 3mo ago	NCT07220109
Bristol-Myers Squibb	A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) Asset: Mezigdomide	Relapsed or Refractory Multiple Myeloma	Active Not Recruiting	Q3 2026 2026-07-18 (est.)	Estimated · fresh Updated 3mo ago	NCT05552976
Chiesi Farmaceutici S.p.A.	Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL Asset: metreleptin	Partial Lipodystrophy	Active Not Recruiting	Q3 2026 2026-07-21 (est.)	Estimated · aging Updated 10mo ago	NCT05164341
Shanghai Vitalgen BioPharma Co., L…	A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency	Aromatic L-amino Acid Decarboxylase Deficiency	Active Not Recruiting	Q3 2026 2026-07-23 (est.)	Estimated · fresh Updated 3mo ago	NCT06432140
BioNTech SE	A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children Asset: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose	SARS-CoV-2 Virus +2	Active Not Recruiting	Q3 2026 2026-07-23 (est.)	Estimated · fresh Updated 3mo ago	NCT05543616
Bristol-Myers Squibb	Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis Asset: BMS-986165	Psoriasis	Active Not Recruiting	Q3 2026 2026-07-25 (est.)	Estimated · aging Updated 9mo ago	NCT04036435
Novavax	A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine Asset: CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant	COVID-19	Completed	Q3 2026 2026-07-26 (est.)	Estimated · aging Updated 12mo ago	NCT06291857
AstraZeneca	D9319C00001- 1L OC Mono Global RCT Asset: Olaparib	Ovarian Cancer	Active Not Recruiting	Q3 2026 2026-07-27 (est.)	Estimated · fresh Updated 4mo ago	NCT04884360
UCB Biopharma SRL	A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Asset: Bimekizumab	Hidradenitis Suppurativa	Active Not Recruiting	Q3 2026 2026-07-28 (est.)	Estimated · fresh Updated 2mo ago	NCT04901195
Innervate Radiopharmaceuticals LLC…	Open-Label Study of 18F-mFBG for Imaging Neuroblastoma Asset: 18F-MFBG	Neuroblastoma	Active Not Recruiting	Q3 2026 2026-07-30 (est.)	Estimated · fresh Updated 3mo ago	NCT04724369
Jiangsu HengRui Medicine Co., Ltd.	A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma Asset: TACE+Camrelizumab+Apatinib mesylate	Hepatocellular Carcinoma	Active Not Recruiting	Q3 2026 2026-07-30 (est.)	Estimated · aging Updated 7mo ago	NCT05320692
CSPC Megalith Biopharmaceutical Co…	Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01） Asset: SYS6010	EGFR-mutated Locally Advanced or Metastatic NSCLC	Recruiting	Q3 2026 2026-07-30 (est.)	Estimated · aging Updated 8mo ago	NCT06927986
ModernaTX, Inc.	A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults Asset: mRNA-1345	Respiratory Syncytial Virus	Active Not Recruiting	Q3 2026 2026-07-30 (est.)	Estimated · aging Updated 11mo ago	NCT06067230
Quoin Pharmaceuticals	Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome Asset: QRX003, 4% Lotion	Netherton Syndrome	Recruiting	Q3 2026 2026-07-30 (est.)	Estimated · aging Updated 12mo ago	NCT06953466
Pfizer	EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease Asset: nirmatrelvir	COVID-19	Recruiting	Q3 2026 2026-07-30 (est.)	Estimated · aging Updated 12mo ago	NCT05261139
Shenyang Sunshine Pharmaceutical C…	SSGJ-707 in Advanced Non-Small Cell Lung Cancer Asset: SSGJ-707	Advanced Non-Small Cell Lung Cancer	Recruiting	Q3 2026 2026-07-30 (est.)	Estimated · aging Updated 12mo ago	NCT06980272
Keymed Biosciences Co.Ltd	Study on the Treatment of Prurigo Nodularis With Stapokibart Injection Asset: Stapokibart	Prurigo Nodularis	Completed	Q3 2026 2026-07-30 (est.)	Estimated · stale Updated 14mo ago	NCT06424470
Merck Sharp & Dohme LLC	Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) Asset: Pembrolizumab	High-risk Non-muscle Invasive Bladder Cancer	Active Not Recruiting	Q3 2026 2026-07-31 (est.)	Estimated · aging Updated 7mo ago	NCT03711032
Jazz Pharmaceuticals	A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers Asset: Zanidatamab	Gastric Neoplasms +2	Active Not Recruiting	Q3 2026 2026-07-31 (est.)	Estimated · fresh Updated 3mo ago	NCT05152147
Alexion Pharmaceuticals, Inc.	A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH Asset: Danicopan	Paroxysmal Nocturnal Hemoglobinuria	Active Not Recruiting	Q3 2026 2026-07-31 (est.)	Estimated · fresh Updated 3mo ago	NCT05389449
BioNTech SE	A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age Asset: BNT162b2 Vaccine	COVID-19 +1	Active Not Recruiting	Q3 2026 2026-07-31 (est.)	Estimated · fresh Updated 3mo ago	NCT07300839
Minghui Pharmaceutical (Hangzhou) …	MHB018A Treatment in Patients With Active Thyroid Eye Disease Asset: MHB018A	Thyroid Associated Ophthalmopathies	Recruiting	Q3 2026 2026-07-31 (est.)	Estimated · fresh Updated 3mo ago	NCT06989918
Cerus Corporation	INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections	Anemia	Active Not Recruiting	Q3 2026 2026-07-31 (est.)	Estimated · fresh Updated 4mo ago	NCT03037164
Biogen	A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD) Asset: Nusinersen	Muscular Atrophy, Spinal	Active Not Recruiting	Q3 2026 2026-07-31 (est.)	Estimated · fresh Updated 5mo ago	NCT04729907
BioNTech SE	A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19 Asset: BNT162b2 (2025/2026 formulation)	COVID-19 +1	Active Not Recruiting	Q3 2026 2026-07-31 (est.)	Estimated · fresh Updated 5mo ago	NCT07222384
Jiangsu HengRui Medicine Co., Ltd.	A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation Asset: Camrelizumab	Hepatocellular Carcinoma (HCC)	Active Not Recruiting	Q3 2026 2026-07-31 (est.)	Estimated · fresh Updated 6mo ago	NCT04639180
MAXVAX Biotechnology Limited Liabi…	Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell) Asset: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)	Respiratory Syncytial Virus (RSV)	Recruiting	Q3 2026 2026-07-31 (est.)	Estimated · aging Updated 7mo ago	NCT07272434
BrightGene Bio-Medical Technology …	A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia Asset: BGM0504	Type 2 Diabetes (T2DM)	Recruiting	Q3 2026 2026-07-31 (est.)	Estimated · aging Updated 8mo ago	NCT07064486
SK Plasma Co., Ltd.	An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a Patients Asset: SKP-0141	Hemophilia A, Severe	Not Yet Recruiting	Q3 2026 2026-07-31 (est.)	Estimated · stale Updated 19mo ago	NCT06738901
AbbVie	A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab Asset: Upadacitinib 15mg Dose	Atopic Dermatitis	Recruiting	Q3 2026 2026-08 (est.)	Estimated · fresh Updated 3mo ago	NCT06389136
Cybin IRL Limited	"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" Asset: CYB003	Major Depressive Disorder	Recruiting	Q3 2026 2026-08 (est.)	Estimated · fresh Updated 3mo ago	NCT06564818
EyePoint Pharmaceuticals, Inc.	A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 Asset: EYP-1901	Wet Age Related Macular Degeneration +1	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · fresh Updated 3mo ago	NCT06668064
AbbVie	ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars	Atrophic Acne Scars	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · stale Updated 13mo ago	NCT05995340
Kodiak Sciences Inc	A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK Asset: Tarcocimab tedromer	Wet Age-related Macular Degeneration	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · aging Updated 8mo ago	NCT06556368
Karyopharm Therapeutics Inc	Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma Asset: Selinexor	Endometrial Cancer	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · fresh Updated 2mo ago	NCT05611931
Cerevance	To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications Asset: CVN424 75 mg	Parkinson Disease	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · fresh Updated 3mo ago	NCT06553027
Eli Lilly and Company	Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) Asset: Retatrutide	Diabetes Mellitus, Type 2	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · fresh Updated 3mo ago	NCT06260722
Kedrion S.p.A.	A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) Asset: Kedrion IVIG 10%	Chronic Primary Immune Thrombocytopenia (ITP)	Recruiting	Q3 2026 2026-08 (est.)	Estimated · fresh Updated 4mo ago	NCT07059000
Grifols Therapeutics LLC	Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) Asset: Alpha-1 MP	Pulmonary Emphysema in Alpha-1 PI Deficiency	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · fresh Updated 4mo ago	NCT01983241
Mirum Pharmaceuticals, Inc.	A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) Asset: Brelovitug 300 mg	Chronic Hepatitis D Infection	Recruiting	Q3 2026 2026-08 (est.)	Estimated · fresh Updated 4mo ago	NCT07298330
Akebia Therapeutics	To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis Asset: Erythropoiesis-Stimulating Agent (ESA)	Anemia of Chronic Kidney Disease	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · fresh Updated 4mo ago	NCT06901505
Pharvaris Netherlands B.V.	Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE Asset: Deucrictibant	Hereditary Angioedema (HAE)	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · fresh Updated 5mo ago	NCT06669754
HALEON	Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice Asset: Stannous fluoride and Potassium nitrate Dentifrice	Dentin Hypersensitivity	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · fresh Updated 5mo ago	NCT07215767
Avidity Biosciences, Inc.	Global Study of Del-desiran for the Treatment of DM1 Asset: AOC 1001 (del-desiran)	DM1 +9	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · fresh Updated 5mo ago	NCT06411288
Ensysce Biosciences	PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) Asset: PF614 capsule	Postoperative Pain, Acute	Recruiting	Q3 2026 2026-08 (est.)	Estimated · fresh Updated 5mo ago	NCT06602271
SK Life Science, Inc.	Cenobamate Open-Label Extension Study for YKP3089C025 Asset: Cenobamate	Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy	Completed	Q3 2026 2026-08 (est.)	Estimated · fresh Updated 6mo ago	NCT03961568
Pacira Pharmaceuticals, Inc	ZILRETTA in Subjects With Shoulder Osteoarthritis Asset: ZILRETTA	Glenohumeral Osteoarthritis	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · aging Updated 8mo ago	NCT06269705
Xenon Pharmaceuticals Inc.	A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Asset: Azetukalner	Major Depressive Disorder	Recruiting	Q3 2026 2026-08 (est.)	Estimated · aging Updated 9mo ago	NCT06775379
Sol-Gel Technologies, Ltd.	Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Asset: Patidegib Topical Gel	Gorlin Syndrome	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · aging Updated 9mo ago	NCT06050122
Cinclus Pharma Holding AB	A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) Asset: Linaprazan glurate 50 mg Twice Daily (BID)	GERD (Gastroesophageal Reflux Disease)	Recruiting	Q3 2026 2026-08 (est.)	Estimated · aging Updated 10mo ago	NCT07037875
AbbVie	A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants	Mid Face Volume Deficit	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · aging Updated 11mo ago	NCT07032597
Pharmbio Korea Co., Ltd.	A Study to Evaluate Safety and Efficacy of PBK_M2502 Asset: PBK_M2502 1-Day	Intestinal Disease +3	Not Yet Recruiting	Q3 2026 2026-08 (est.)	Estimated · aging Updated 11mo ago	NCT07114406
AbbVie	A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. Asset: Pomalidomide	Multiple Myeloma	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · stale Updated 13mo ago	NCT03539744
Sunshine Lake Pharma Co., Ltd.	Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer Asset: Lerotinib	Esophageal Cancer	Recruiting	Q3 2026 2026-08 (est.)	Estimated · stale Updated 14mo ago	NCT04415853
iVascular S.L.U.	Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy Asset: 1-month DAPT	Coronary Artery Disease	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · stale Updated 14mo ago	NCT05952206
Shanghai Mabgeek Biotech.Co.Ltd	Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis Asset: Placebo	Prurigo Nodularis	Recruiting	Q3 2026 2026-08 (est.)	Estimated · stale Updated 15mo ago	NCT06779136
CELL Technologies Inc.	Bone Marrow Aspirate Concentrate (BMAC) Treatment for Knee Osteoarthritis Asset: Autologous Bone Marrow Aspirate Concentrate	Knee Osteoarthritis +1	Not Yet Recruiting	Q3 2026 2026-08 (est.)	Estimated · stale Updated 25mo ago	NCT06216028
Yantai LNC Biotechnology Singapore…	Clinical Study of 18F-Alfatide Injection PET/CT Asset: 18F-Alfatide Injection	Non-Small Cell Lung Cancer NSCLC	Not Yet Recruiting	Q3 2026 2026-08 (est.)	Estimated · stale Updated 26mo ago	NCT06416852
Sinovac (Dalian) Vaccine Technolog…	Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Asset: Varicella Vaccine	Varicella (Chickenpox) +1	Not Yet Recruiting	Q3 2026 2026-08-01 (est.)	Estimated · fresh Updated 4mo ago	NCT07473427
Merck Sharp & Dohme LLC	A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) Asset: IV Tulisokibart	Ulcerative Colitis	Active Not Recruiting	Q3 2026 2026-08-01 (est.)	Estimated · fresh Updated 4mo ago	NCT06052059
Innovent Biologics (Suzhou) Co. Ltd.	Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity Asset: IBI362	Overweight +2	Recruiting	Q3 2026 2026-08-01 (est.)	Estimated · fresh Updated 4mo ago	NCT07469800
BioMarin Pharmaceutical	Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia Asset: Vosoritide	Hypochondroplasia	Active Not Recruiting	Q3 2026 2026-08-01 (est.)	Estimated · fresh Updated 6mo ago	NCT06455059
Gan & Lee Pharmaceuticals.	A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM) Asset: GZR4	Diabetes	Active Not Recruiting	Q3 2026 2026-08-01 (est.)	Estimated · aging Updated 7mo ago	NCT06767735
Jiangxi Kvvit Pharmaceutical Co., …	A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension Asset: Suraxavir Marboxil	Influenza	Not Yet Recruiting	Q3 2026 2026-08-01 (est.)	Estimated · aging Updated 11mo ago	NCT07113392
Daiichi Sankyo	A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) Asset: T-DXd	Advanced Cancer +1	Recruiting	Q3 2026 2026-08-03 (est.)	Estimated · aging Updated 9mo ago	NCT06174987
Amgen	A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis Asset: Apremilast	Plaque Psoriasis	Active Not Recruiting	Q3 2026 2026-08-06 (est.)	Estimated · aging Updated 8mo ago	NCT06088199
UCB Biopharma SRL	A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis Asset: Bimekizumab	Axial Spondyloarthritis +3	Active Not Recruiting	Q3 2026 2026-08-07 (est.)	Estimated · fresh Updated 2mo ago	NCT04436640
Gan & Lee Pharmaceuticals.	A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise Asset: GZR18	Type 2 Diabetes Mellitus (T2DM)	Active Not Recruiting	Q3 2026 2026-08-07 (est.)	Estimated · aging Updated 7mo ago	NCT06777238
Sanofi	A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population Asset: Yellow fever vaccine (live)	Yellow Fever Immunization	Recruiting	Q3 2026 2026-08-08 (est.)	Estimated · fresh Updated 4mo ago	NCT07103148
Incyte Corporation	A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo Asset: Ruxolitinib Cream	NonSegmental Vitiligo	Recruiting	Q3 2026 2026-08-10 (est.)	Estimated · aging Updated 7mo ago	NCT06548360
AstraZeneca	Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis. Asset: Nexium 20mg	Erosive Esophagitis	Active Not Recruiting	Q3 2026 2026-08-14 (est.)	Estimated · fresh Updated 3mo ago	NCT05267613
Genzyme, a Sanofi Company	Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B Asset: Fitusiran	Hemophilia	Active Not Recruiting	Q3 2026 2026-08-15 (est.)	Estimated · aging Updated 11mo ago	NCT03974113
Shanghai Fudan-Zhangjiang Bio-Phar…	FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer Asset: FDA018-ADC	Triple Negative Breast Cancer	Active Not Recruiting	Q3 2026 2026-08-18 (est.)	Estimated · fresh Updated 5mo ago	NCT06519370
ViiV Healthcare	A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 Asset: CAB LA + RPV LA	HIV Infections	Recruiting	Q3 2026 2026-08-19 (est.)	Estimated · fresh Updated 3mo ago	NCT06694805
Amgen	A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity Asset: Dazodalibep	Sjogren's Syndrome	Active Not Recruiting	Q3 2026 2026-08-19 (est.)	Estimated · fresh Updated 6mo ago	NCT06104124
Merck Sharp & Dohme LLC	Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) Asset: pembrolizumab/vibostolimab	Carcinoma, Non-Small-Cell Lung	Active Not Recruiting	Q3 2026 2026-08-19 (est.)	Estimated · aging Updated 11mo ago	NCT05298423
Longboard Pharmaceuticals	A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) Asset: LP352	Dravet Syndrome	Recruiting	Q3 2026 2026-08-21 (est.)	Estimated · fresh Updated 3mo ago	NCT06660394
EMD Serono Research & Development …	Avelumab Program Rollover Study Asset: Avelumab	Solid Tumors	Active Not Recruiting	Q3 2026 2026-08-21 (est.)	Estimated · fresh Updated 3mo ago	NCT03815643
UCB Biopharma SRL	A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Asset: Brivaracetam	Childhood Absence Epilepsy +1	Active Not Recruiting	Q3 2026 2026-08-24 (est.)	Estimated · fresh Updated 4mo ago	NCT04666610
AstraZeneca	A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease Asset: AZD9833	ER-Positive HER2-Negative Breast Cancer	Active Not Recruiting	Q3 2026 2026-08-24 (est.)	Estimated · aging Updated 9mo ago	NCT04711252
Novartis Pharmaceuticals	Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer Asset: JDQ443	Non-Small Cell Lung Cancer	Active Not Recruiting	Q3 2026 2026-08-25 (est.)	Estimated · fresh Updated 3mo ago	NCT05132075
Panbela Therapeutics, Inc.	Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer Asset: SBP-101	Pancreatic Cancer Metastatic +2	Recruiting	Q3 2026 2026-08-29 (est.)	Estimated · stale Updated 20mo ago	NCT05254171
Pfizer	MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Asset: Elranatamab	Multiple Myeloma	Recruiting	Q3 2026 2026-08-30 (est.)	Estimated · fresh Updated 2mo ago	NCT06152575
Takeda	A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults Asset: Tetravalent Dengue Vaccine (TDV)	Dengue Fever	Active Not Recruiting	Q3 2026 2026-08-30 (est.)	Estimated · fresh Updated 5mo ago	NCT07047521
Keymed Biosciences Co.Ltd	Study of CM310 in Adolescent Subjects With Atopic Dermatis Asset: CM310	Atopic Dermatitis	Active Not Recruiting	Q3 2026 2026-08-30 (est.)	Estimated · aging Updated 9mo ago	NCT06495229
Hutchison Medipharma Limited	Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC Asset: Savolitinib	Non-small Cell Lung Cancer	Active Not Recruiting	Q3 2026 2026-08-30 (est.)	Estimated · aging Updated 10mo ago	NCT05009836
Beletalent (Zhuhai) Pharmaceutical…	Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy Asset: TNTL	Non-Proliferative Diabetic Retinopathy	Recruiting	Q3 2026 2026-08-30 (est.)	Estimated · aging Updated 10mo ago	NCT06817265
Il-Yang Pharm. Co., Ltd.	Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer Asset: Ilaprazole	Peptic Ulcer	Recruiting	Q3 2026 2026-08-30 (est.)	Estimated · stale Updated 13mo ago	NCT06284876
Daiichi Sankyo	Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) Asset: Trastuzumab deruxtecan	Gastric Cancer, Adenocarcinoma +1	Active Not Recruiting	Q3 2026 2026-08-31 (est.)	Estimated · fresh Updated 6mo ago	NCT04704934
Hoffmann-La Roche	A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression Asset: Sefaxersen (RO7434656)	Primary IgA Nephropathy	Recruiting	Q3 2026 2026-08-31 (est.)	Estimated · fresh Updated 3mo ago	NCT05797610
Bayer	A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy Asset: BAY3723113	Obstructive Hypertrophic Cardiomyopathy	Active Not Recruiting	Q3 2026 2026-08-31 (est.)	Estimated · fresh Updated 3mo ago	NCT07023341
Pfizer	A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease. Asset: RSVpreF	Respiratory Syncytial Virus (RSV)	Recruiting	Q3 2026 2026-08-31 (est.)	Estimated · fresh Updated 3mo ago	NCT07543380
AMAG Pharmaceuticals, Inc.	A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD) Asset: Ferumoxytol	Chronic Kidney Disease; Iron Deficiency Anemia	Recruiting	Q3 2026 2026-08-31 (est.)	Estimated · fresh Updated 3mo ago	NCT03619850
Hansoh BioMedical R&D Company	Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure Asset: HS-20093	Osteosarcoma	Active Not Recruiting	Q3 2026 2026-08-31 (est.)	Estimated · fresh Updated 3mo ago	NCT06935409
Anthos Therapeutics, Inc.	Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) Asset: Abelacimab	Atrial Fibrillation (AF)	Recruiting	Q3 2026 2026-08-31 (est.)	Estimated · fresh Updated 3mo ago	NCT05712200
Sichuan Jishengtang Pharmaceutical…	Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney) Asset: Wujia Yizhi granules	Alzheimer's Dementia	Recruiting	Q3 2026 2026-08-31 (est.)	Estimated · fresh Updated 6mo ago	NCT06534723
Kringle Pharma, Inc.	Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar Asset: KP-100LI	Vocal Fold Scar	Recruiting	Q3 2026 2026-08-31 (est.)	Estimated · aging Updated 7mo ago	NCT05627648
Daewon Pharmaceutical Co., Ltd.	Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma Asset: Experimental	Perennial Allergic Rhinitis Accompanied by Asthma	Recruiting	Q3 2026 2026-08-31 (est.)	Estimated · aging Updated 10mo ago	NCT07168473
Galderma R&D	Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis Asset: Nemolizumab	Moderate-to-Severe Atopic Dermatitis	Active Not Recruiting	Q3 2026 2026-08-31 (est.)	Estimated · stale Updated 20mo ago	NCT03989206
AbbVie	A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab Asset: Adalimumab	Juvenile Psoriatic Arthritis	Recruiting	Q3 2026 2026-09 (est.)	Estimated · fresh Updated 5mo ago	NCT06100744
Disc Medicine, Inc	Study of Bitopertin in Participants With EPP or XLP (APOLLO) Asset: Placebo	Erythropoietic Protoporphyria (EPP) +1	Active Not Recruiting	Q3 2026 2026-09 (est.)	Estimated · fresh Updated 3mo ago	NCT06910358
Clarity Pharmaceuticals Ltd	Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy Asset: 64Cu-SAR-bisPSMA	Prostate Cancer +1	Recruiting	Q3 2026 2026-09 (est.)	Estimated · fresh Updated 3mo ago	NCT06056830
Alkermes, Inc.	Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder Asset: OLZ/SAM	Schizophrenia +1	Recruiting	Q3 2026 2026-09 (est.)	Estimated · fresh Updated 5mo ago	NCT05303064
TWi Biotechnology, Inc.	An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) Asset: AC-203	Generalized Epidermolysis Bullosa Simplex	Active Not Recruiting	Q3 2026 2026-09 (est.)	Estimated · fresh Updated 2mo ago	NCT06073132
vTv Therapeutics	Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Asset: Cadisegliatin 800 mg QD	Diabetes Mellitus, Type 1	Recruiting	Q3 2026 2026-09 (est.)	Estimated · fresh Updated 2mo ago	NCT06334133
Jiangsu BioJeTay Biotechnology Co.…	Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients Asset: STSP-0601 for Injection	Hemophilia	Recruiting	Q3 2026 2026-09 (est.)	Estimated · fresh Updated 2mo ago	NCT06922045
Eli Lilly and Company	A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) Asset: LY3650150	Perennial Allergic Rhinitis (PAR)	Recruiting	Q3 2026 2026-09 (est.)	Estimated · fresh Updated 3mo ago	NCT06339008
Curium US LLC	Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer Asset: Copper Cu 64 PSMA I&T	Prostate Cancer +1	Recruiting	Q3 2026 2026-09 (est.)	Estimated · fresh Updated 3mo ago	NCT06235151
argenx	A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy Asset: Empasiprubart	Multifocal Motor Neuropathy (MMN) +1	Active Not Recruiting	Q3 2026 2026-09 (est.)	Estimated · fresh Updated 4mo ago	NCT06742190
Cook MyoSite	Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence Asset: AMDC-USR (iltamiocel)	Stress Urinary Incontinence	Active Not Recruiting	Q3 2026 2026-09 (est.)	Estimated · fresh Updated 4mo ago	NCT03104517
Eli Lilly and Company	A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) Asset: Baricitinib	Systemic Juvenile Idiopathic Arthritis	Recruiting	Q3 2026 2026-09 (est.)	Estimated · fresh Updated 5mo ago	NCT04088396
ScandiBio Therapeutics AB	Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease Asset: Combined metabolic activators	Alzheimer Disease	Recruiting	Q3 2026 2026-09 (est.)	Estimated · fresh Updated 5mo ago	NCT07062198
Pharmazz, Inc.	Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke Asset: Drug: Normal Saline	Acute Ischemic Stroke +1	Recruiting	Q3 2026 2026-09 (est.)	Estimated · fresh Updated 6mo ago	NCT05691244
Atea Pharmaceuticals, Inc.	C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV Asset: Bemnifosbuvir-Ruzasvir (BEM/RZR)	HEPATITIS C VIRUS CHRONIC INFECTION	Active Not Recruiting	Q3 2026 2026-09 (est.)	Estimated · aging Updated 7mo ago	NCT06868264
Shandong Suncadia Medicine Co., Ltd.	A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy Asset: HRS-1893 Tablets	Obstructive Hypertrophic Cardiomyopathy	Recruiting	Q3 2026 2026-09 (est.)	Estimated · aging Updated 11mo ago	NCT07021976
EyeBiotech Ltd.	A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME Asset: Ranibizumab	Diabetic Macular Edema (DME)	Active Not Recruiting	Q3 2026 2026-09 (est.)	Estimated · aging Updated 11mo ago	NCT06571045
Qilu Pharmaceutical Co., Ltd.	GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer Asset: GM1	Chemotherapy-induced Peripheral Neuropathy (CIPN)	Recruiting	Q3 2026 2026-09 (est.)	Estimated · aging Updated 11mo ago	NCT06994507
Intra-Cellular Therapies, Inc.	Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Asset: Lumateperone	Major Depressive Disorder	Recruiting	Q3 2026 2026-09 (est.)	Estimated · aging Updated 12mo ago	NCT05850689
Supernus Pharmaceuticals, Inc.	Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) Asset: SPN-812	Attention-Deficit/Hyperactivity Disorder	Active Not Recruiting	Q3 2026 2026-09 (est.)	Estimated · aging Updated 12mo ago	NCT02736656
Mabwell (Shanghai) Bioscience Co.,…	A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer Asset: 9MW2821	Advanced Urothelial Carcinoma	Recruiting	Q3 2026 2026-09 (est.)	Estimated · stale Updated 15mo ago	NCT06196736
Rophibio, Inc.	A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration Asset: RBS-001 Solution for intravitreal injection	Neovascular Age-related Macular Degeneration (nAMD)	Not Yet Recruiting	Q3 2026 2026-09 (est.)	Estimated · stale Updated 15mo ago	NCT06470373
Bio-Thera Solutions	BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer Asset: Recombinant humanized anti-PD-1 monoclonal antibody injection	Cervical Cancer	Recruiting	Q3 2026 2026-09 (est.)	Estimated · stale Updated 17mo ago	NCT06123884
Alfasigma S.p.A.	Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis Asset: Filgotinib	Ulcerative Colitis	Active Not Recruiting	Q3 2026 2026-09 (est.)	Estimated · stale Updated 17mo ago	NCT02914535
Chia Tai Tianqing Pharmaceutical G…	A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients Asset: TQB2450+Anlotinib	Small Cell Lung Cancer Limited Stage	Not Yet Recruiting	Q3 2026 2026-09 (est.)	Estimated · stale Updated 24mo ago	NCT06469879
Salutaris Medical Devices, Inc.	Adjunct Episcleral Brachytherapy for PCV Asset: Aflibercept Injection	Age-Related Macular Degeneration +1	Not Yet Recruiting	Q3 2026 2026-09 (est.)	Estimated · stale Updated 34mo ago	NCT05251636
CSPC Zhongnuo Pharmaceutical (Shij…	Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment Asset: Mitoxantrone hydrochloride liposome injection	Recurrent Metastatic Nasopharyngeal Carcinoma	Not Yet Recruiting	Q3 2026 2026-09 (est.)	Estimated · stale Updated 41mo ago	NCT05717764
Newron Pharmaceuticals SPA	Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia Asset: Evenamide 15 mg bid	Treatment-resistant Schizophrenia	Recruiting	Q3 2026 2026-09-01 (est.)	Estimated · fresh Updated 3mo ago	NCT07184619
Incyte Corporation	Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients Asset: Tafasitamab	Diffuse Large B-cell Lymphoma	Active Not Recruiting	Q3 2026 2026-09-01 (est.)	Estimated · fresh Updated 3mo ago	NCT04824092
Daewoong Pharmaceutical Co. LTD.	Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients Asset: DWP16001 Placebo	Type 2 Diabetic Nephropathy	Not Yet Recruiting	Q3 2026 2026-09-01 (est.)	Estimated · stale Updated 22mo ago	NCT06606093
Boehringer Ingelheim	Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment Asset: zongertinib	Lung Cancer, Non-squamous, Non-small Cell	Active Not Recruiting	Q3 2026 2026-09-02 (est.)	Estimated · fresh Updated 3mo ago	NCT06151574
UCB BIOSCIENCES, Inc.	A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome Asset: fenfluramine	Dravet Syndrome	Active Not Recruiting	Q3 2026 2026-09-03 (est.)	Estimated · fresh Updated 3mo ago	NCT06118255
H. Lundbeck A/S	A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine Asset: Eptinezumab	Chronic Migraine in Children	Recruiting	Q3 2026 2026-09-05 (est.)	Estimated · fresh Updated 4mo ago	NCT04965675
Innovent Biologics (Suzhou) Co. Ltd.	IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia Asset: IBI306	Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia	Recruiting	Q3 2026 2026-09-06 (est.)	Estimated · fresh Updated 3mo ago	NCT07473960
Galaxy Therapeutics INC	SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial	Intracranial Aneurysm	Active Not Recruiting	Q3 2026 2026-09-10 (est.)	Estimated · fresh Updated 6mo ago	NCT05831202
GlaxoSmithKline	A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age Asset: Candidate varicella vaccine	Chickenpox	Recruiting	Q3 2026 2026-09-10 (est.)	Estimated · aging Updated 7mo ago	NCT06855160
Priovant Therapeutics, Inc.	A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis Asset: Brepocitinib PO QD	Uveitis, Posterior +2	Active Not Recruiting	Q3 2026 2026-09-11 (est.)	Estimated · fresh Updated 6mo ago	NCT06431373
Applied Biology, Inc.	Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia Asset: DA-007	Chemotherapy Induced Alopecia +1	Not Yet Recruiting	Q3 2026 2026-09-11 (est.)	Estimated · stale Updated 14mo ago	NCT06762548
Merck Sharp & Dohme LLC	Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) Asset: Pembrolizumab	Endometrial Neoplasms	Active Not Recruiting	Q3 2026 2026-09-15 (est.)	Estimated · stale Updated 13mo ago	NCT04634877
Vertex Pharmaceuticals Incorporated	An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant Asset: Biological/Vaccine	Type 1 Diabetes +1	Recruiting	Q3 2026 2026-09-17 (est.)	Estimated · fresh Updated 4mo ago	NCT06832410
Han Xu, M.D., Ph.D., FAPCR, Sponso…	Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms Asset: Topotecan - usual	SCLC	Active Not Recruiting	Q3 2026 2026-09-18 (est.)	Estimated · aging Updated 10mo ago	NCT07145333
Hangzhou Zhongmei Huadong Pharmace…	Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes Asset: HDM1005 1	Obesity & Overweight	Recruiting	Q3 2026 2026-09-20 (est.)	Estimated · aging Updated 7mo ago	NCT07279194
Karuna Therapeutics, Inc., a Brist…	A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) Asset: KarXT	Alzheimer Disease	Recruiting	Q3 2026 2026-09-21 (est.)	Estimated · fresh Updated 3mo ago	NCT06585787
Cardiol Therapeutics Inc.	CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) Asset: CardiolRx	Recurrent Pericarditis	Recruiting	Q3 2026 2026-09-21 (est.)	Estimated · fresh Updated 4mo ago	NCT06708299
Biogen	A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus Asset: Litifilimab	Lupus Erythematosus, Systemic	Active Not Recruiting	Q3 2026 2026-09-27 (est.)	Estimated · fresh Updated 5mo ago	NCT04961567
Ocugen	A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease Asset: OCU410ST	Stargardt Disease	Active Not Recruiting	Q3 2026 2026-09-28 (est.)	Estimated · fresh Updated 3mo ago	NCT05956626
GlaxoSmithKline	Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Asset: Depemokimab	Eosinophilic Granulomatosis With Polyangiitis	Active Not Recruiting	Q3 2026 2026-09-29 (est.)	Estimated · aging Updated 8mo ago	NCT05263934
argenx	A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis Asset: Efgartigimod PH20 SC	Generalized Myasthenia Gravis	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · aging Updated 7mo ago	NCT06392386
GlaxoSmithKline	An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study Asset: RSVPreF3 OA vaccine	Respiratory Syncytial Virus Infections	Active Not Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · fresh Updated 3mo ago	NCT06534892
Pfizer	Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Asset: Avelumab	Advanced Malignancies +4	Active Not Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · fresh Updated 3mo ago	NCT05059522
AstraZeneca	A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Asset: Dato-DXd	Metastatic Non-small Cell Lung Cancer	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · fresh Updated 4mo ago	NCT06417814
Glycomine, Inc.	A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG Asset: GLM101 (Part A, Double-blind)	Phosphomannomutase 2 Deficiency +1	Active Not Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · fresh Updated 4mo ago	NCT06892288
GlaxoSmithKline	Linerixibat Long-term Safety, and Tolerability Study Asset: Linerixibat	Cholestasis	Active Not Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · fresh Updated 5mo ago	NCT04167358
Sinovac Biotech Co., Ltd	Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine Asset: Sinovac rabies vaccine	Rabies (Healthy Volunteers)	Not Yet Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · fresh Updated 5mo ago	NCT07416110
Biogen	A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus Asset: Litifilimab	Lupus Erythematosus, Systemic	Active Not Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · fresh Updated 5mo ago	NCT04895241
UpTru Inc.	Study to Confirm the AuthenTicity of Point of Care Urine samplEs Using Oral fluoreScein Sodium in adulTs With substancE Use Disorder (ATTESTED) Asset: Fluorescein	Substance Use Disorder (SUD)	Not Yet Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · fresh Updated 5mo ago	NCT07356349
Chongqing Claruvis Pharmaceutical …	A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults Asset: Recombinant Botulinum Toxin Type A for injection (YY001)	Upper Limb Spasticity	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · fresh Updated 5mo ago	NCT06783114
Amryt Pharma	Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy Asset: Metreleptin	Generalized Lipodystrophy	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · fresh Updated 6mo ago	NCT06502990
Innovent Biopharmaceutical Technol…	A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis Asset: IBI112	Psoriasis	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · aging Updated 7mo ago	NCT07265284
Beijing Continent Pharmaceutical C…	Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis Asset: Pirfenidone Capsules	Pneumoconiosis	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · aging Updated 7mo ago	NCT05288179
Beijing Pearl Biotechnology Limite…	A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) Asset: PLB1001	Non-small Cell Lung Cancer	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · aging Updated 12mo ago	NCT05989542
Innovent Biologics (Suzhou) Co. Ltd.	Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer Asset: Pemetrexed	Non-Small Cell Lung Cancer	Active Not Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · aging Updated 12mo ago	NCT05116462
Fujian Shengdi Pharmaceutical Co.,…	A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes Asset: HRS9531 Injection	Type 2 Diabetes	Active Not Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · stale Updated 13mo ago	NCT06649344
CSPC Ouyi Pharmaceutical Co., Ltd.	A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder Asset: Dextromethorphan and Bupropion Sustained-Release Tablets	Major Depressive Disorder (MDD)	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · stale Updated 14mo ago	NCT06958692
Allist Pharmaceuticals, Inc.	JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation Asset: JAB-21822	Advanced Non-squamous Non-small-cell Lung Cancer +1	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · stale Updated 15mo ago	NCT06416410
Shanghai JMT-Bio Inc.	A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations Asset: JMT101	Locally Advanced or Metastatic Non-squamous NSCLC +2	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · stale Updated 19mo ago	NCT06735391
Hansoh BioMedical R&D Company	ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer Asset: HS-20093	Small Cell Lung Cancer	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · stale Updated 21mo ago	NCT06498479
SyneuRx International (Taiwan) Corp	An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults Asset: NaBen®	Refractory Schizophrenia	Recruiting	Q3 2026 2026-09-30 (est.)	Estimated · stale Updated 58mo ago	NCT03094429
EyePoint Pharmaceuticals, Inc.	A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 Asset: EYP-1901	Wet Age Related Macular Degeneration +1	Active Not Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 3mo ago	NCT06683742
Senseye, Inc.	REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool	PTSD - Post Traumatic Stress Disorder	Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 3mo ago	NCT07280065
UroGen Pharma Ltd.	A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer Asset: UGN-104	Upper Urinary Tract Urothelial Carcinoma +1	Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 6mo ago	NCT06774131
Debiopharm International SA	A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial) Asset: Debio 4326	Central Precocious Puberty	Active Not Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 3mo ago	NCT06129539
Actinogen Medical	Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease Asset: Xanamem	Dementia Moderate +2	Active Not Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 2mo ago	NCT06125951
Privo Technologies	A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers Asset: PRV211 (Intraoperative Cisplatin System)	Oral Squamous Cell Carcinoma	Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 2mo ago	NCT05893888
AbbVie	Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD Asset: Aflibercept (EYLEA®)	AMD +5	Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 3mo ago	NCT05407636
Organon and Co	Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects Asset: tapinarof cream, 1%	Plaque Psoriasis	Active Not Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 3mo ago	NCT05172726
Merz North America, Inc.	A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States Asset: NT 201	Neuromuscular Agents +9	Active Not Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 3mo ago	NCT07122193
Novadip Biosciences	A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia. Asset: NVD003	Congenital Pseudarthrosis of Tibia	Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 3mo ago	NCT07112443
Mirum Pharmaceuticals, Inc.	Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) Asset: Maralixibat	Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)	Active Not Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 3mo ago	NCT06553768
Celldex Therapeutics	A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) Asset: barzolvolimab	Chronic Spontaneous Urticaria	Active Not Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 3mo ago	NCT06455202
Celldex Therapeutics	A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria Asset: barzolvolimab	Chronic Spontaneous Urticaria	Active Not Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 3mo ago	NCT06445023
Xenon Pharmaceuticals Inc.	A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Asset: XEN1101	Focal Onset Seizures	Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 4mo ago	NCT05716100
Tenax Therapeutics, Inc.	LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF Asset: TNX-103	Pulmonary Hypertension	Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 5mo ago	NCT05983250
Loxo Oncology, Inc.	A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Asset: Pirtobrutinib	Chronic Lymphocytic Leukemia +1	Active Not Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 5mo ago	NCT04965493
Mesoblast, Ltd.	Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain Asset: Rexlemestrocel-L + HA mixture	Degenerative Disc Disease	Active Not Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 5mo ago	NCT06325566
Akeso	AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer Asset: AK112, Gemcitabine, Cisplatin	Biliary Tract Cancer	Active Not Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 6mo ago	NCT06591520
Pharmazz, Inc.	A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent Asset: Normal Saline	Hypovolemic Shock	Not Yet Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 6mo ago	NCT05251181
Eli Lilly and Company	Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) Asset: Retatrutide	Type 2 Diabetes	Active Not Recruiting	Q4 2026 2026-10 (est.)	Estimated · fresh Updated 6mo ago	NCT06297603
AFT Pharmaceuticals, Ltd.	A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain Asset: Combogesic® IV (fixed-dose combination containing acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion)	Acute Pain	Not Yet Recruiting	Q4 2026 2026-10 (est.)	Estimated · aging Updated 8mo ago	NCT07225634
AFT Pharmaceuticals, Ltd.	A Study of Combogesic® 325 in Adolescent Patients With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery Asset: Combogesic® tablets	Post Operative Pain, Acute	Not Yet Recruiting	Q4 2026 2026-10 (est.)	Estimated · aging Updated 8mo ago	NCT07225140
Ebima Clifford Okundaye	Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression Asset: QRX-3	Chronic Kidney Diseases +2	Not Yet Recruiting	Q4 2026 2026-10 (est.)	Estimated · aging Updated 10mo ago	NCT06866236
Zhejiang Sunshine Mandi Pharmaceut…	Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris Asset: Clascoterone	Acne Vulgaris	Recruiting	Q4 2026 2026-10 (est.)	Estimated · aging Updated 12mo ago	NCT06403501
GIE Medical	Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus	Esophageal Stricture	Recruiting	Q4 2026 2026-10 (est.)	Estimated · aging Updated 12mo ago	NCT05561114
Inmunotek S.L.	Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. Asset: 10,000 MG01 +10,000 T521	Rhinitis, Allergic +2	Recruiting	Q4 2026 2026-10 (est.)	Estimated · stale Updated 14mo ago	NCT04898283
CSPC ZhongQi Pharmaceutical Techno…	Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors Asset: Sirolimus for Injection (Albumin-bound)	HR+/HER2- Advanced/Metastatic Breast Cancer	Not Yet Recruiting	Q4 2026 2026-10 (est.)	Estimated · stale Updated 15mo ago	NCT06929325
Humacyte, Inc.	To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis Asset: Acellular Tissue Engineered Vessel (ATEV)	End Stage Renal Disease (ESRD)	Active Not Recruiting	Q4 2026 2026-10 (est.)	Estimated · stale Updated 16mo ago	NCT05908084
Chia Tai Tianqing Pharmaceutical G…	D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure Asset: D-1553 Tablet	Non Small Cell Lung Cancer	Recruiting	Q4 2026 2026-10 (est.)	Estimated · stale Updated 26mo ago	NCT06300177
Novo Nordisk A/S	A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation Asset: Ziltivekimab	Heart Failure +1	Recruiting	Q4 2026 2026-10-01 (est.)	Estimated · fresh Updated 3mo ago	NCT06200207
argenx	A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia Asset: efgartigimod PH20 SC	Primary Immune Thrombocytopenia	Active Not Recruiting	Q4 2026 2026-10-01 (est.)	Estimated · fresh Updated 6mo ago	NCT04812925
Beijing Dongfang Biotech Co., Ltd.	A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin Asset: Exendin-4 Fc fusion protein injection(1.2mg）	Type2 Diabetes Mellitus	Active Not Recruiting	Q4 2026 2026-10-01 (est.)	Estimated · aging Updated 10mo ago	NCT06257966
Takeda	A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy Asset: TAK-861	Narcolepsy Type 1 (NT1) +1	Recruiting	Q4 2026 2026-10-02 (est.)	Estimated · fresh Updated 4mo ago	NCT07363720
Karuna Therapeutics, Inc., a Brist…	A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) Asset: KarXT	Psychosis Associated With Alzheimer's Disease	Recruiting	Q4 2026 2026-10-05 (est.)	Estimated · fresh Updated 3mo ago	NCT05511363
Bristol-Myers Squibb	A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis Asset: BMS-986278	Idiopathic Pulmonary Fibrosis	Active Not Recruiting	Q4 2026 2026-10-06 (est.)	Estimated · fresh Updated 3mo ago	NCT06003426
Regeneron Pharmaceuticals	Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) Asset: Dupilumab	Atopic Dermatitis	Active Not Recruiting	Q4 2026 2026-10-07 (est.)	Estimated · aging Updated 12mo ago	NCT02612454
Pfizer	A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine Asset: Rimegepant	Migraine	Recruiting	Q4 2026 2026-10-08 (est.)	Estimated · fresh Updated 3mo ago	NCT06616194
CSPC ZhongQi Pharmaceutical Techno…	A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type) Asset: Hydroxocobalamin Chloride Injection	Methylmalonic Acidemia (MMA)	Not Yet Recruiting	Q4 2026 2026-10-08 (est.)	Estimated · aging Updated 10mo ago	NCT07163364
Incyte Corporation	Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) Asset: Ruxolitinib Cream	Hidradenitis Suppurativa	Recruiting	Q4 2026 2026-10-09 (est.)	Estimated · fresh Updated 3mo ago	NCT06959225
Incyte Corporation	Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) Asset: Ruxolitinib Cream	Hidradenitis Suppurativa	Recruiting	Q4 2026 2026-10-09 (est.)	Estimated · fresh Updated 3mo ago	NCT06958211
Hangzhou Zhongmei Huadong Pharmace…	A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects Asset: MC2-01 cream	Plaque Psoriasis	Active Not Recruiting	Q4 2026 2026-10-10 (est.)	Estimated · fresh Updated 5mo ago	NCT07357831
Hangzhou Zhongmei Huadong Pharmace…	Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus Asset: HDM1002 200 mg	Type 2 Diabetes	Recruiting	Q4 2026 2026-10-10 (est.)	Estimated · aging Updated 9mo ago	NCT07193459
Biocodex	Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome Asset: Saccharomyces Boulardii 250 MG	IBS (Irritable Bowel Syndrome) +2	Recruiting	Q4 2026 2026-10-11 (est.)	Estimated · aging Updated 8mo ago	NCT07168434
Janssen Research & Development, LLC	A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC Asset: Apalutamide	Metastatic Castrate-sensitive Prostate Cancer	Active Not Recruiting	Q4 2026 2026-10-12 (est.)	Estimated · fresh Updated 4mo ago	NCT05884398
Shanghai JMT-Bio Inc.	JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer Asset: JSKN003	Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants	Recruiting	Q4 2026 2026-10-13 (est.)	Estimated · stale Updated 15mo ago	NCT06846437
Sandoz	Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis Asset: CYB704	Relapsing Multiple Sclerosis	Active Not Recruiting	Q4 2026 2026-10-14 (est.)	Estimated · fresh Updated 4mo ago	NCT06847724
Birch BioMed Inc	Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients Asset: IP1 control cream (Vehicle base)	Burn Scar +1	Recruiting	Q4 2026 2026-10-15 (est.)	Estimated · aging Updated 8mo ago	NCT06807021
Suzhou Alphamab Co., Ltd.	Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors Asset: KN057	Hemophilia A Without Inhibitor +1	Active Not Recruiting	Q4 2026 2026-10-15 (est.)	Estimated · aging Updated 10mo ago	NCT06569108
Han Xu, M.D., Ph.D., FAPCR, Sponso…	Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers Asset: Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes	Type 2 Diabetes	Active Not Recruiting	Q4 2026 2026-10-18 (est.)	Estimated · aging Updated 12mo ago	NCT07033585
Incyte Corporation	A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) Asset: Povorcitinib	Prurigo Nodularis	Active Not Recruiting	Q4 2026 2026-10-19 (est.)	Estimated · fresh Updated 3mo ago	NCT06516952
Incyte Corporation	A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) Asset: Povorcitinib	Prurigo Nodularis	Active Not Recruiting	Q4 2026 2026-10-19 (est.)	Estimated · fresh Updated 3mo ago	NCT06516965
Bristol-Myers Squibb	A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) Asset: Deucravacitinib	Systemic Lupus Erythematosus	Active Not Recruiting	Q4 2026 2026-10-19 (est.)	Estimated · aging Updated 7mo ago	NCT05617677
Bristol-Myers Squibb	A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus Asset: Deucravacitinib	Systemic Lupus Erythematosus	Active Not Recruiting	Q4 2026 2026-10-19 (est.)	Estimated · aging Updated 7mo ago	NCT05620407
Otsuka Pharmaceutical Development …	A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia Asset: SEP-363856	Schizophrenia	Recruiting	Q4 2026 2026-10-20 (est.)	Estimated · fresh Updated 2mo ago	NCT06894212
Biogen	A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus Asset: Litifilimab	Subacute Cutaneous Lupus Erythematosus +1	Active Not Recruiting	Q4 2026 2026-10-20 (est.)	Estimated · fresh Updated 2mo ago	NCT05531565
LEO Pharma	A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis Asset: Tralokinumab + TCS	Atopic Dermatitis	Recruiting	Q4 2026 2026-10-20 (est.)	Estimated · fresh Updated 4mo ago	NCT06311682
Amgen	A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State Asset: Dazodalibep	Sjögren's Syndrome (SS)	Active Not Recruiting	Q4 2026 2026-10-22 (est.)	Estimated · fresh Updated 6mo ago	NCT06245408
CSL Behring	Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products Asset: Recombinant single-chain factor VIII (rVIII-SingleChain)	Congenital Hemophilia A	Active Not Recruiting	Q4 2026 2026-10-26 (est.)	Estimated · fresh Updated 2mo ago	NCT06738485
Novartis Pharmaceuticals	Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events Asset: Inclisiran sodium 300 mg	Coronary Artery Disease	Active Not Recruiting	Q4 2026 2026-10-26 (est.)	Estimated · fresh Updated 3mo ago	NCT05360446
Galderma R&D	A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Asset: Nemolizumab	Prurigo Nodularis	Active Not Recruiting	Q4 2026 2026-10-26 (est.)	Estimated · aging Updated 8mo ago	NCT04204616
Amgen	A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis Asset: Rocatinlimab	Prurigo Nodularis	Active Not Recruiting	Q4 2026 2026-10-28 (est.)	Estimated · fresh Updated 6mo ago	NCT06527404
Merck Sharp & Dohme LLC	A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) Asset: Belzutifan	Carcinoma, Renal Cell	Active Not Recruiting	Q4 2026 2026-10-28 (est.)	Estimated · aging Updated 11mo ago	NCT05239728
Akeso	A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC Asset: Cadonilimab (AK104)	NSCLC (Non-small Cell Lung Cancer)	Recruiting	Q4 2026 2026-10-28 (est.)	Estimated · stale Updated 16mo ago	NCT06617416
Merck Sharp & Dohme LLC	A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) Asset: Pembrolizumab	Carcinoma, Renal Cell	Active Not Recruiting	Q4 2026 2026-10-29 (est.)	Estimated · stale Updated 20mo ago	NCT04736706
Novartis Pharmaceuticals	Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) Asset: Ianalumab	Primary Immune Thrombocytopenia (ITP)	Active Not Recruiting	Q4 2026 2026-10-29 (est.)	Estimated · fresh Updated 3mo ago	NCT05653349
Taiho Oncology, Inc.	REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) Asset: TAS6417	Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation	Active Not Recruiting	Q4 2026 2026-10-29 (est.)	Estimated · fresh Updated 4mo ago	NCT05973773
Vertex Pharmaceuticals Incorporated	A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy Asset: VX-121/TEZ/D-IVA	Cystic Fibrosis	Active Not Recruiting	Q4 2026 2026-10-30 (est.)	Estimated · aging Updated 10mo ago	NCT05444257
AstraZeneca	A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma	Asthma	Recruiting	Q4 2026 2026-10-30 (est.)	Estimated · fresh Updated 3mo ago	NCT06471257
CSPC Ouyi Pharmaceutical Co., Ltd.	A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes Asset: Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR	Type 2 Diabetes	Active Not Recruiting	Q4 2026 2026-10-30 (est.)	Estimated · fresh Updated 3mo ago	NCT07026968
Laekna Limited	Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Asset: Afuresertib	Breast Cancer	Active Not Recruiting	Q4 2026 2026-10-30 (est.)	Estimated · fresh Updated 3mo ago	NCT04851613
Beijing Continent Pharmaceutical C…	A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis Asset: Hydronidone Capsules	Chronic Hepatitis B With Hepatic Fibrosis	Recruiting	Q4 2026 2026-10-30 (est.)	Estimated · fresh Updated 3mo ago	NCT07343778
Cali Pharmaceuticals LLC	Phase 3 Bunionectomy Study Asset: CPL-01	Postoperative Pain +1	Not Yet Recruiting	Q4 2026 2026-10-30 (est.)	Estimated · fresh Updated 3mo ago	NCT07490496
Kind Pharmaceuticals LLC	A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia Asset: AND017 capsules	Anemia Due to Chronic Kidney Disease	Recruiting	Q4 2026 2026-10-30 (est.)	Estimated · fresh Updated 3mo ago	NCT07494409
Janssen Research & Development, LLC	A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation Asset: Milvexian	Atrial Fibrillation	Active Not Recruiting	Q4 2026 2026-10-31 (est.)	Estimated · fresh Updated 3mo ago	NCT05757869
Viatris Innovation GmbH	A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus Asset: Cenerimod	Lupus Erythematosus, Systemic	Active Not Recruiting	Q4 2026 2026-10-31 (est.)	Estimated · fresh Updated 3mo ago	NCT05648500
Teva Branded Pharmaceutical Produc…	A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations Asset: TEV-56248	Asthma	Active Not Recruiting	Q4 2026 2026-10-31 (est.)	Estimated · fresh Updated 3mo ago	NCT06052267
Annexon, Inc.	A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) Asset: Vonaprument	Geographic Atrophy	Active Not Recruiting	Q4 2026 2026-10-31 (est.)	Estimated · aging Updated 8mo ago	NCT06510816
Longboard Pharmaceuticals	A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) Asset: LP352	Developmental and Epileptic Encephalopathy	Recruiting	Q4 2026 2026-10-31 (est.)	Estimated · fresh Updated 3mo ago	NCT06719141
Viatris Innovation GmbH	A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus Asset: Cenerimod	Lupus Erythematosus, Systemic	Active Not Recruiting	Q4 2026 2026-10-31 (est.)	Estimated · fresh Updated 3mo ago	NCT05672576
Takeda	TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations Asset: TAK-788	Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	Active Not Recruiting	Q4 2026 2026-10-31 (est.)	Estimated · fresh Updated 3mo ago	NCT04129502
AstraZeneca	Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients Asset: Capivasertib	Breast Cancer	Active Not Recruiting	Q4 2026 2026-10-31 (est.)	Estimated · fresh Updated 3mo ago	NCT06635447
Hoffmann-La Roche	A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) Asset: Alectinib	Non-Small Cell Lung Cancer	Active Not Recruiting	Q4 2026 2026-10-31 (est.)	Estimated · fresh Updated 4mo ago	NCT03178552
Sarepta Therapeutics, Inc.	A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) Asset: Eteplirsen	Muscular Dystrophy, Duchenne	Active Not Recruiting	Q4 2026 2026-10-31 (est.)	Estimated · fresh Updated 4mo ago	NCT03992430
Immutep S.A.S.	Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy Asset: eftilagimod alpha	Breast Carcinoma	Active Not Recruiting	Q4 2026 2026-10-31 (est.)	Estimated · stale Updated 19mo ago	NCT05747794
Jiangsu HengRui Medicine Co., Ltd.	Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative Asset: SHR6390	Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer	Active Not Recruiting	Q4 2026 2026-10-31 (est.)	Estimated · stale Updated 23mo ago	NCT04842617
Arthrosi Therapeutics	Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302) Asset: AR882 50 mg	Gout +3	Completed	Q4 2026 2026-11 (est.)	Estimated · stale Updated 15mo ago	NCT06439602
Eli Lilly and Company	A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight Asset: Tirzepatide	Type 1 Diabetes +2	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 5mo ago	NCT06914895
Sichuan Kelun-Biotech Biopharmaceu…	A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Asset: SKB264	Non-Small Cell Lung Cancer	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 4mo ago	NCT06448312
Definium Therapeutics US, Inc.	A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) Asset: DT120	Generalized Anxiety Disorder	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 4mo ago	NCT06809595
Seqirus	A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age Asset: aQIV or aTIV	Influenza, Human	Completed	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 2mo ago	NCT06087640
Sichuan Baili Pharmaceutical Co., …	A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) Asset: BL-B01D1	Nasopharyngeal Carcinoma	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 3mo ago	NCT06118333
SK Life Science, Inc.	Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures Asset: Xcopri	Partial Epilepsy	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 3mo ago	NCT05067634
Sinovac Biotech Co., Ltd	Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years Asset: experimental vaccine	Epidemic Meningitis +1	Not Yet Recruiting	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 3mo ago	NCT07505888
DBV Technologies	Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)	Allergy +1	Recruiting	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 3mo ago	NCT07003919
Definium Therapeutics US, Inc.	A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge) Asset: DT120	Major Depressive Disorder	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 4mo ago	NCT06941844
AbbVie	A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease Asset: ABBV-444	Dry Eye Disease	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 4mo ago	NCT07284381
Immunic AG	Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis Asset: IMU-838 tablets	Multiple Sclerosis	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 4mo ago	NCT05134441
Immunic AG	Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis Asset: IMU-838 tablets	Multiple Sclerosis, Relapsing-Remitting	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 4mo ago	NCT05201638
Eli Lilly and Company	A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight Asset: Tirzepatide	Type 1 Diabetes +2	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 5mo ago	NCT06962280
Wooshin Labottach Co., Ltd.	Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis	Nail Psoriasis +2	Recruiting	Q4 2026 2026-11 (est.)	Estimated · fresh Updated 5mo ago	NCT07029516
Nuance Hearing	A Prospective, Open-label, Pivotal Study to Assess Spectacle Hearing Aid Safety and Efficacy	Hearing Loss Mixed	Recruiting	Q4 2026 2026-11 (est.)	Estimated · aging Updated 7mo ago	NCT07282028
Waterstone Pharmaceutical (Wuhan) …	A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia Asset: WS016	Hyperkalemia	Recruiting	Q4 2026 2026-11 (est.)	Estimated · aging Updated 7mo ago	NCT07251309
Lynk Pharmaceuticals Co., Ltd	A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis Asset: LNK01001	Ankylosing Spondylitis	Recruiting	Q4 2026 2026-11 (est.)	Estimated · aging Updated 8mo ago	NCT07237568
Medicure	Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency Asset: Pyridoxal Phosphate	Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency	Recruiting	Q4 2026 2026-11 (est.)	Estimated · aging Updated 9mo ago	NCT04706013
Eli Lilly and Company	A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight Asset: Orforglipron	OSA +1	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · aging Updated 9mo ago	NCT06649045
Nanjing Chia-tai Tianqing Pharmace…	A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Asset: NTQ5082 capsules 200 mg	Paroxysmal Nocturnal Hemoglobinuria	Not Yet Recruiting	Q4 2026 2026-11 (est.)	Estimated · aging Updated 10mo ago	NCT07177859
medac GmbH	Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. Asset: Methotrexate	Moderate to Severe Atopic Dermatitis	Recruiting	Q4 2026 2026-11 (est.)	Estimated · aging Updated 10mo ago	NCT06239311
LG Chem	A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series Asset: LBVD	Diphtheria +5	Recruiting	Q4 2026 2026-11 (est.)	Estimated · aging Updated 12mo ago	NCT06947499
Cambium Bio Limited	Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye Asset: CAM-101	Dry Eye Disease +3	Not Yet Recruiting	Q4 2026 2026-11 (est.)	Estimated · stale Updated 14mo ago	NCT06903611
Qilu Pharmaceutical Co., Ltd.	Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer Asset: QLG1080	Prostate Cancer	Not Yet Recruiting	Q4 2026 2026-11 (est.)	Estimated · stale Updated 17mo ago	NCT06837896
Akeso	A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma Asset: cadonilimab	Gastric and Gastroesophageal Junction Adenocarcinoma	Recruiting	Q4 2026 2026-11 (est.)	Estimated · stale Updated 24mo ago	NCT06341335
NewAmsterdam Pharma	Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease Asset: Obicetrapib	Atherosclerotic Cardiovascular Disease	Active Not Recruiting	Q4 2026 2026-11 (est.)	Estimated · stale Updated 25mo ago	NCT05202509
Epygenix	An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome Asset: Clemizole HCl	Lennox Gastaut Syndrome	Recruiting	Q4 2026 2026-11-01 (est.)	Estimated · fresh Updated 3mo ago	NCT05066217
Bristol-Myers Squibb	A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Asset: KarXT	Bipolar-I Disorder With Mania or Mania With Mixed Features	Recruiting	Q4 2026 2026-11-01 (est.)	Estimated · fresh Updated 3mo ago	NCT06951698
Scholar Rock, Inc.	Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab Asset: Apitegromab	Spinal Muscular Atrophy +9	Active Not Recruiting	Q4 2026 2026-11-01 (est.)	Estimated · stale Updated 13mo ago	NCT05626855
Bristol-Myers Squibb	A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2) Asset: KarXT	Bipolar Disorder Type I With Mania or Mania With Mixed Features	Recruiting	Q4 2026 2026-11-02 (est.)	Estimated · fresh Updated 3mo ago	NCT06951711
CMG Pharmaceutical Co. Ltd	Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia Asset: CMG190303(Dapagliflozin/Rosuvastatin)	Dyslipidemia +1	Recruiting	Q4 2026 2026-11-04 (est.)	Estimated · fresh Updated 6mo ago	NCT06772168
Genzyme, a Sanofi Company	Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX Asset: Fitusiran	Hemophilia	Active Not Recruiting	Q4 2026 2026-11-05 (est.)	Estimated · aging Updated 7mo ago	NCT03754790
Novartis Pharmaceuticals	24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up Asset: LOU064 (blinded)	Chronic Spontaneous Urticaria	Recruiting	Q4 2026 2026-11-06 (est.)	Estimated · fresh Updated 3mo ago	NCT05677451
LEAF4Life, Inc.	Efficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress Syndrome Asset: LEAF-4L6715	Acute Respiratory Distress Syndrome	Not Yet Recruiting	Q4 2026 2026-11-09 (est.)	Estimated · stale Updated 21mo ago	NCT06640777
LaNova Medicines Zhejiang Co., Ltd.	LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. Asset: LM-302	Locally Advanced or Metastatic GC and GCJ Adenocarcinoma	Active Not Recruiting	Q4 2026 2026-11-10 (est.)	Estimated · fresh Updated 5mo ago	NCT06351020
Gan & Lee Pharmaceuticals.	A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin Asset: GZR4	Diabetes	Recruiting	Q4 2026 2026-11-10 (est.)	Estimated · aging Updated 7mo ago	NCT07165223
Janssen Research & Development, LLC	A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE Asset: Milvexian	Ischemic Stroke; Ischemic Attack, Transient	Active Not Recruiting	Q4 2026 2026-11-11 (est.)	Estimated · fresh Updated 3mo ago	NCT05702034

Unlock 295 more readouts · filter by sponsor, indication, and time window

Upgrade to Pro

Methodology & caveats

Why this is harder than it looks

There is no single “readout date” on any public registry. A Phase 3 trial generates three different dated events, only one of which is registered:

Primary completion date — last patient finishes the primary endpoint analysis. This is the only event published on ClinicalTrials.gov.
Topline announcement — the company press release / 8-K that actually moves the stock. Typically lands 3–9 months after primary completion. Not registered anywhere structured.
Results posted to CT.gov — full data uploaded to the registry. Mandated by FDAAA within 12 months of primary completion (often hits the deadline).

Most sponsor-supplied dates are ESTIMATED and can slip silently. Plenty of "active" trials haven't been touched on CT.gov in 12+ months — the date you see may be a stale ghost.

How we label every row

We anchor on CT.gov primary completion (the only public, structured signal) and combine date type (ACTUAL vs ESTIMATED) with the time since the sponsor last updated the trial record:

Read out — results have been posted to ClinicalTrials.gov (definitive).
Completed · awaiting — primary completion is ACTUAL but no results yet (topline often already announced; sponsor has 12 months under FDAAA to post).
Estimated · fresh / aging / stale — sponsor estimate, with last-update freshness in 3 buckets (≤6 mo / 6–12 mo / >12 mo).

What we explicitly don't claim

We do not predict topline announcement dates and we do not score per-trial slip risk. Both would require SEC EDGAR full-text NCT linking and historical version snapshots — separate enrichments we've scoped but not built. Other free retail calendars conflate ACTUAL/ESTIMATED dates and don't flag staleness; we label them so you don't have to guess which dates are credible.

Coverage

Source: ClinicalTrials.gov v2 API. We list industry-sponsored Phase 3 trials with primary completion in the last 6 months or next 12+ months. Excluded: TERMINATED, WITHDRAWN, SUSPENDED. Phase 2 readouts are out of scope today (5x volume, separate sprint).